Measurable residual disease in chronic lymphocytic leukemia
Measurable residual disease (MRD) is defined as the presence of residual cancer cells after treatment in patients with clinically undetectable disease, who would otherwise be considered in complete remission. It is a highly sensitive parameter which indicates the disease burden and predicts survival...
Main Authors: | Giulia Benintende, Federico Pozzo, Idanna Innocenti, Francesco Autore, Alberto Fresa, Giovanni D’Arena, Valter Gattei, Luca Laurenti |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-02-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1112616/full |
Similar Items
-
Minimal Residual Disease Surveillance in Chronic Lymphocytic Leukemia by Fluorescence-Activated Cell Sorting
by: Shimrit Ringelstein-Harlev, et al.
Published: (2014-10-01) -
Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia
by: Jiguang Wang, et al.
Published: (2014-12-01) -
Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia
by: Marisa J. L. Aitken, et al.
Published: (2021-09-01) -
CD200 and Chronic Lymphocytic Leukemia: Biological and Clinical Relevance
by: Giovanni D’Arena, et al.
Published: (2020-11-01) -
Laboratory analysis of 124 chronic lymphocytic leukemia cases: Single center study
by: Shams Salah Mahdi, et al.
Published: (2024-12-01)